GENEVA, November 14, 2022–(BUSINESS WIRE)–MEDIMAPS GROUP (www.medimapsgroup.com), a Swiss/global medical technology company specializing in image processing software for bone health assessment, announced today that its new method for improving osteoporotic fracture risk assessment, Trabecular Bone Score (TBS iNsight™), an AI-enhanced bone microarchitecture surrogate, is now available on OsteoSys Co. diagnostic platforms. , ltd. OsteoSys is the leading brand of bone densitometers in Korea and the third largest supplier of DXA scanning equipment in the world. .
TBS iNsight™ is available on Primus Whole Body DXA from OsteoSys, their high-end DXA scanning product. The agreement extends global access to Medimaps’ technology to clinicians from countries in Southeast Asia, Europe and South America. Financial terms were not disclosed.
Medimaps has obtained CE Mark 2797 for TBS iNsight™, FDA 510(k) clearance in the United States, and it is authorized in over 60 countries worldwide, including Japan and South Korea. The TBS is also now refundable in the United States and some European countries and is working towards reimbursement in Japan and Korea. The use of TBS is recommended by many local, national and international medical societies such as Switzerland, France, Italy, Germany, Spain, as well as the United States, China and Japan.
“Bone structure is just as important as bone mineral density (BMD) when diagnosing and treating osteoporosis,” said Dr. Young-bok AHN, CEO and Founder of OsteoSys. “Alongside BMD, Medimaps TBS iNsight™ provides a more complete picture of the patient’s fracture risk. We see TBS iNsight as a viable option integrated with our DXA scanners to treat osteoporosis, a rapidly growing health problem as the world’s population ages.
“Our proprietary and patented technology is enhanced by a multi-layered deep learning approach, making it applicable to a wide range of image modalities and resolutions,” said Professor Didier Hans, CEO and co-founder of MedimapsGroup. “TBS demonstrates improved diagnostic accuracy for primary and secondary osteoporosis and in women and men, and it appears sensitive to changes over time that result from effective treatment (with increasing TBS ) or continued bone loss in the absence of effective treatment (with TBS Because it is seamlessly integrated into the assessment of BMD, TBS will be applicable in a number of clinical settings, ranging from X-ray based opportunistic screening, patient risk profiling and presurgical assessments.
Osteoporosis is a condition of major concern among aging patient populations. Patients at risk for osteoporotic fractures often receive a BMD assessment, which only measures bone quantity but not bone quality. Medimaps Group’s TBS iNsight works alongside BMD and clinical risk factors to analyze bone micro-architecture as an assessment of bone quality. Within moments, the software application provides practitioners with an easy-to-interpret score to quickly identify and classify patients’ fracture risk and implement an intervention plan. Medimaps technology uses the same images acquired for BMD assessment (but also digital X-ray images or projected CT images). Patients are not exposed to additional radiation and the TBS integrates seamlessly into a physician’s clinical workflow to provide a comprehensive structured report.
About OsteoSys Co. Ltd.
Founded in 2000 and based in Seoul, South Korea, OsteoSys manufactures bone densitometer devices to treat and diagnose osteoporosis through a wide range of body and peripheral DXA scanning offerings. Learn more at http://osteosys.com/englsh/.
About Medimaps Group
Medimaps Group’s medical imaging software applications based on patented versatile technology with artificial intelligence capabilities provide healthcare solutions that integrate seamlessly into the workflow for the benefit of the patient. TBS iNsight™ (Osteo) has been used for years in clinical practice around the world in the field of osteoporosis. It has become the new gold standard for bone texture assessment in routine clinical practice. The TBS has gained international recognition with over 900 peer-reviewed scientific publications and is included in numerous guidelines and used by over 30,000 physicians worldwide, including leading healthcare institutions. Learn more at https://www.medimapsgroup.com/.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20221113005059/en/
+1 240 994 0248